U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524634) titled 'Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis' on April 06.
Brief Summary: This research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition. The purpose of this study is to evaluate whether elranatamab, a type of immunotherapy drug, can produce deep remissions and organ recovery in people with newly diagnosed AL amyloidosis, and to compare two different dosing schedules.
Elranatamab (brand name ELREXFIO™) is an investigational (experimental) drug in the setting...